Press Releases

March 31, 2020

Valneva Announces the Publication of its 2019 Universal Registration Document

March 25, 2020

Valneva Reports Positive End-of-Phase 2 Chikungunya Meeting with the U.S. FDA; Sets Stage for Phase 3 Study

March 24, 2020

Valneva Provides Business Update on COVID-19 Situation

March 8, 2020

Valneva Announces FDA Approval of IXIARO® Shelf Life Extension to 36 Months; New US Military RFP Issued

February 27, 2020

Valneva Reports Record Product Sales and Major Pipeline Progress in 2019

February 3, 2020

Valneva Announces New $85 Million Financing Arrangement with Leading US Healthcare Funds Deerfield and OrbiMed

January 14, 2020

Valneva: US DoD Exercises Option on IXIARO® Supply Contract Bringing Total Value to $70 Million

January 9, 2020

Valneva Expands its Commercial Operations with the Opening of its French Commercial Office

January 7, 2020

Valneva Announces End of Phase 2 Meeting with the FDA for its Chikungunya Vaccine Candidate

December 20, 2019

Valneva Completes Delisting from the Vienna Stock Exchange

1
2
3
…
33